A Randomized, Placebo- and Comparator-controlled, Double-blind, Multiple (Ascending) Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen-Cilag
- 03 Jun 2016 Status changed from recruiting to completed.
- 05 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Aug 2015 New trial record